Anders Blanck

Anders Blanck is Director-General for Lif – the association for the research-based pharmaceutical companies in Sweden, representing 90 companies involved in pharmaceutical R&D and innovation.

He is chair of the Board of the Swedish e-Verification organization (e-VIS), and member of the Swedish Government’s Life Science Advisory Board and several other Boards and think-tanks within the Swedish Life Science-sector.

At European level he is a Board member of EFPIA (European Federation for the research based pharmaceutical industry) and vice chair of EFPIA’s Heads of National Association’s Council. At global level he is member of IFPMA’s (International Federation of Pharmaceutical Manufacturers and Associations) Council as well as Heads of National Associations Committee.

Previously, he has been the Director-General for Health and Head of the Healthcare Division at the Swedish Ministry of Health and Social Affairs, and Board member of the Karolinska Institute and the Swedish Anti-Corruption Institute.

Articles: Anders Blanck

Swedish Pharma Sustainability Manifesto

Sweden / Anders Blanck, CEO of LIF, the industry organisation for the research-based pharmaceutical industry in Sweden, describes the Sustainability Strategy that the pharma industry in Sweden is now launching. Central to the Strategy is a Manifesto with nine commitments that covers the entire value chain of medicines – from research and development through manufacturing, to marketing…

Sweden as a Global Testbed for AMR Incentive Models

Sweden / Anders Blanck, CEO of Lif, the trade association for the research-based Swedish pharmaceutical industry, writes about the challenges the world faces from antimicrobial resistance (AMR). Sweden has for decades been a pioneer in the field, and Blanck believes that Sweden is an excellent test market for various incentive models that, scaled up to European and…

Can Sweden take the lead in Precision Medicine?

Sweden / Anders Blanck of Lif, the trade association for the research-based Swedish pharmaceutical industry, outlines the steps already being put in place for Sweden to become a leading country in the implementation of precision medicine. Blanck highlights the impact of Sweden’s December 2019 Life Science Strategy – which includes initiatives on molecular diagnostics and treatments, health…